RCM Technologies (RCMT) Q4 2025 earnings summary

Executive summary

• Revenue for the current quarter rose 12.4% year-over-year to $86.5 million, with gross profit up 12.6% to $24.3 million.

• GAAP net income for the quarter was $6.1 million ($0.80 per diluted share), up from $2.9 million ($0.37 per share) in the prior year quarter.

• For the full year, revenue increased 14.7% to $319.4 million, and gross profit grew 10.2% to $87.9 million.

• Full-year GAAP net income reached $16.3 million ($2.14 per diluted share), compared to $13.3 million ($1.68 per share) last year.

• Adjusted EBITDA for the year was $30.7 million, up 18.9% year-over-year.

Financial highlights

• Adjusted net income per diluted share for the quarter was $0.77, up from $0.49 in the prior year quarter.

• Adjusted EBITDA for the quarter was $9.3 million, a 49.0% increase year-over-year.

• Full-year adjusted net income per diluted share was $2.50, up from $2.03 last year.

• Gross profit margin for the year was 27.5%, with quarterly margin at 28.1%.

• Cash and cash equivalents at year-end were $2.9 million, down from $4.7 million the previous year.

Segment performance

• Specialty Health Care led with $164.1 million in annual revenue and a 28.9% gross margin.

• Engineering contributed $120.5 million in revenue with a 22.7% gross margin.

• Life Sciences, Data and Solutions posted $34.8 million in revenue and a 37.8% gross margin.